乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

AASLD

<乌鸦传媒>Efruxifermin Led to NASH Resolution, Fibrosis Improvement in Mid-Stage Trial

Both 50- and 28-mg doses improved fibrosis vs placebo, without worsening of NASH

<乌鸦传媒>Maralixibat Takes Out the Itch of Rare Liver Disease

Ileal bile acid transporter inhibitor could become second drug for PFIC

<乌鸦传媒>Odevixibat Shows 'Encouraging Results' for Kids With Alagille Syndrome

Significant improvements in itching, bile acid levels for rare, life-threatening liver disorder

<乌鸦传媒>Acamprosate Appears Safe for People With AUD and Liver Disease

Phase II data suggest drug is well-tolerated and can reduce cravings in this group of patients

<乌鸦传媒>Tenofovir, Vaccine Combo Eliminates Mom-to-Child HBV Transmission

100% success rate even without the use of hepatitis B immunoglobulin

<乌鸦传媒>BP Control Beneficial for Liver Transplant Recipients

Patients who kept their blood pressure under 140/90 mm Hg had better kidney function at 1 year

<乌鸦传媒>Earlier Terlipressin May Be Better for HRS-AKI in Acute-on-Chronic Liver Failure

More acute kidney injury reversals at 7 days and lower mortality with initiation at 12 hours

<乌鸦传媒>Low Carb Diet Boosts Weight Loss for Liver Transplant Recipients With Obesity

LCD also positively impacted patients' metabophenotype

<乌鸦传媒>Pandemic's Impact on Liver Disease in the Spotlight at Liver Meeting

A roundup of news from the AASLD annual meeting

<乌鸦传媒>Is Weight Protective for NAFLD Patients Undergoing Transplant?

UNOS data showed differences in waitlist removal, all-cause mortality based on obesity status

<乌鸦传媒>Hepatology Not Immune to Workplace Discrimination

Women, racial/ethnic minorities most likely to experience discriminatory behavior

<乌鸦传媒>Need for Liver Transplants Rising Sharply in Seniors

Post-transplant mortality still higher versus younger patients, but improving over time

<乌鸦传媒>'Concerning' Opioid Prescribing in Patients With Cirrhosis

PCPs more than twice as likely as gastroenterologists to prescribe opioids

<乌鸦传媒>How Do Patients With Cirrhosis Respond to the COVID Vaccine?

Italian researchers examine data in this understudied subset of patients

<乌鸦传媒>Blood-Based Biomarkers Prove Mettle in Liver Disease Diagnosis

Data part of initiative to qualify biomarkers to help diagnose fibrosis or NASH

<乌鸦传媒>FMT Benefits Last a Few Years in Severe Alcoholic Hepatitis Patients

More research needed to determine impact on clinical outcomes versus standard of care

<乌鸦传媒>Simvastatin-Treated Liver Donors May Aid Transplant Patient Outcomes

Improved graft survival versus placebo in small randomized trial

<乌鸦传媒>Iron Load in NAFLD Tied to Higher Liver Cancer Risk

Clinical surveillance of serum iron levels may be worth monitoring, researcher says

<乌鸦传媒>How Did the COVID Pandemic Affect Liver Transplant Outcomes?

There was an impact on patient survival rates, but researcher acknowledges several confounders

<乌鸦传媒>NASH Patients Are Entitled to a 'Bill of Rights'

Advocacy group encourages a "partnership" between clinicians and patients

<乌鸦传媒>Fewer Hepatitis C Patients Seeking Treatment of Late

Accelerated declines in 2020 only the latest in a downward trajectory

<乌鸦传媒>COVID-19 and MIS-C: Two Diseases, One Virus in Kids

Both clinical profiles and even outcomes varied, researcher says

<乌鸦传媒>Chronic Liver Conditions Raise Risk of Death in COVID-19 Patients

Alcohol appears to play major role, researcher says

<乌鸦传媒>How South Korea Avoided a COVID-19 Lockdown

Test, trace, treat and transparency key to controlling outbreak, expert reports

<乌鸦传媒>Trial Finds Semaglutide Resolves NASH in Many Obese Adults

But "unexpected" lack of improvement in fibrosis stage vs placebo

<乌鸦传媒>Reassuring New Data for Pregnant Women With Cirrhosis

Risk of liver complications may be much lower than previously reported

<乌鸦传媒>Kratom-Linked Hepatotoxicity on the Rise in the U.S.

Clinicians should be aware that the herbal supplement can cause liver injury, researcher says

<乌鸦传媒>HCV Combo Pill a Winner in Untreated Cirrhotic Patients

High SVR12 rate suggests 8-week treatment could be used for this population

<乌鸦传媒>Minorities Sicker than Whites at Liver Transplant Referral

Blacks had highest MELD scores at waitlist registration among racial-ethnic groups

<乌鸦传媒>Novel Thyroid Beta Receptor Agonist Cut LDL-C in NAFLD Patients

Small phase II study also found reductions in liver fat vs placebo

<乌鸦传媒>Regular Aspirin Use Tied to Reduction in HCC Risk

Significant benefit apparent after ≥5 years of use at average dose of at least 1.5 tablets/week

<乌鸦传媒>Do Patients with Chronic Liver Disease Face Higher DILI Risk?

Research suggests a link of which drug developers should be aware, expert says

<乌鸦传媒>Hepatitis C Treatment Works Well for Young Kids

Nearly all children treated with sofosbuvir/ledipasvir achieved sustained response

<乌鸦传媒>Pregnant Women at Risk for HCV Benefit from Universal Screen

Test deemed more efficient, cost-effective diagnostic approach versus risk-based screening

<乌鸦传媒>'De-Fatting' Tx May Give Discarded Livers New Life

Ex vivo perfusion system plus therapy reduced fat in steatotic livers

<乌鸦传媒>AASLD Poster Roundup: Gender, Insurance, Weight and Waitlists

Selections from poster sessions at the annual Liver Meeting

<乌鸦传媒>Liver Meeting to Focus on Practice Matters Along with Science

Topics range from 'day in the life' of a hepatology consultant to novel NASH therapies

<乌鸦传媒>Unlabeled Ingredients in 'Herbal' Supplements Seen Causing Liver Injury

Common culprits: body-building, weight-loss products

<乌鸦传媒>Experts Raise Red Flag over Fatty Liver Disease

Paints gloomy picture for population health, economy

<乌鸦传媒>PBC Drug Promising in New Setting

Lowers levels of enzyme in primary sclerosing cholangitis

1